Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT02999841
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT02999841
-
- Other papers using this trial's data
- Effect of acarbose and vildagliptin on plasma trimethylamine N-oxide levels in patients with type 2 diabetes mellitus: a 6-month, two-arm randomized controlled trial
- Metagenomic analysis reveals crosstalk between gut microbiota and glucose-lowering drugs targeting the gastrointestinal tract in Chinese patients with type 2 diabetes: a 6 month, two-arm randomised trial
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02999841. Randomized; no masking; primary purpose treatment. Start 2016-03 (registry gives no type); primary completion 2017-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients
- Acronym
- VISA-T2DM
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Obesity
- Intervention (Drug)
- Acarbose
- Intervention (Drug)
- Vildagliptin
- Lead sponsor
- Peking University
Record details
- Record id
cardio:ct-nct02999841- Content hash
92d8cb561bbd96998f09f70b2a19814d36c2c563c16c39a1f563ef203e5abe4d